Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

There were associations for GLP-1 RA treatment vs placebo with improvements in restrained eating and emotional eating behavior and in mental health-related QOL. HealthDay News — For patients ...

The review included three randomized controlled trials that enrolled 410 smokers, 207 of whom received a GLP-1 RA. One study was ... The US study compared exenatide (2 mg weekly) with placebo ...

76, with low certainty) between GLP-1 RAs and placebo. GLP-1 RA treatment was associated with significantly improved restrained eating and reduced emotional eating. This finding, said the authors ...

But the pause brought renewed attention to one of the biggest challenges in health care today, one that played a role in GIC’s woes: the high price of popular GLP-1 drugs to treat obesity.

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still prefer to lose weight without using medications. For those preferring a drug ...

Risks for prostate cancer metastasis or death appeared lower with GLP-1 RA use compared with use of other antidiabetic drugs. Patients with prostate cancer who take glucagon-like peptide-1 ...

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced ...